﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 12:10:16 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>HammasPoli’s calming clinic environment brings peace of mind to patients</title><link>https://news.cision.com/planmeca-oy/r/hammaspoli-s-calming-clinic-environment-brings-peace-of-mind-to-patients,c4358519</link><guid isPermaLink="false">cision5379994</guid><description><![CDATA[Founded in autumn 2025 in Iisalmi, Finland, HammasPoli has quickly become a trusted local dental clinic, welcoming patients with the genuine warmth of a family-owned practice. The clinic environment is characterised by a sense of calm, where wandering thoughts and the sounds of dentistry are gently soothed by the woodland-inspired interior elements and forest green colours. Designed by Plandent Finland and partners, the refined clinic concept is complemented by Planmeca’s ultramodern dental units and imaging systems.
[HammasPoli_dental_clinic_01.jpg]

Situated in the Northern Savonia]]></description><pubDate>Tue, 09 Jun 2026 10:07:24 GMT</pubDate></item><item><title>Four leading Canadian healthcare providers unite on Sectra’s cloud solution to enhance city-wide radiology collaboration and patient care</title><link>https://news.cision.com/sectra/r/four-leading-canadian-healthcare-providers-unite-on-sectra-s-cloud-solution-to-enhance-city-wide-rad,c4359273</link><guid isPermaLink="false">cision5379707</guid><description><![CDATA[Linköping, Sweden & Mississauga, ON – June 9, 2026 – International medical imaging IT and cybersecurity company Sectra (https://sectra.com/) (STO: SECT B) is implementing its fully-managed cloud enterprise imaging solution, Sectra One Cloud, across four healthcare providers in Ontario, Canada—Hamilton Health Sciences, St. Joseph’s Healthcare Hamilton, Norfolk General Hospital, and West Haldimand General Hospital. This city-wide cloud transition will help their 16 sites optimize radiology and breast imaging workflows and strengthen collaboration, leading to better patient care across the]]></description><pubDate>Tue, 09 Jun 2026 06:35:00 GMT</pubDate></item><item><title>The last day of trading with the warrants of series TO6 in Peptonic Medical AB is today, June 9, 2026</title><link>https://news.cision.com/peptonic-medical-ab/r/the-last-day-of-trading-with-the-warrants-of-series-to6-in-peptonic-medical-ab-is-today--june-9--202,c4359371</link><guid isPermaLink="false">cision5379568</guid><description><![CDATA[NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.

Today, June 9, 2026, is the last day of trading with the warrants of series TO6 (“Warrants” or “TO6”) in Peptonic Medical AB (“Peptonic” or the “Company”). The exercise period for the Warrants runs up to and including June 12, 2026. Each Warrant gives the owner]]></description><pubDate>Tue, 09 Jun 2026 06:00:00 GMT</pubDate></item><item><title>Implantica announces launch of 20[th] RefluxStop® Center of Excellence in Spain, part of a world-renowned US hospital group</title><link>https://news.cision.com/implantica/r/implantica-announces-launch-of-20-th--refluxstop--center-of-excellence-in-spain--part-of-a-world-ren,c4359398</link><guid isPermaLink="false">cision5379587</guid><description><![CDATA[Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, establishes a new RefluxStop® Center of Excellence in Spain, MD Anderson Cancer Center Madrid-Hospiten, part of the world-renowned U.S. hospital group MD Anderson Cancer group.
The RefluxStop® procedure was performed by Oscar Alonso MD, PhD, GI Surgical Oncologist and Head of Robotic Gastrointestinal Surgery at MD Anderson Cancer Center Madrid-Hospiten, marking the]]></description><pubDate>Tue, 09 Jun 2026 06:00:00 GMT</pubDate></item><item><title>Peptonic Medical AB – Major shareholder exercises warrants to subscribe for shares</title><link>https://news.cision.com/peptonic-medical-ab/r/peptonic-medical-ab---major-shareholder-exercises-warrants-to-subscribe-for-shares,c4358988</link><guid isPermaLink="false">cision5379048</guid><description><![CDATA[Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces today, 8 June 2026, that the Company has been informed by the major shareholder, Maida Vale Capital AB, that it intends to exercise Series TO6 warrants to subscribe for shares amounting to approximately SEK 2.7 million. Maida Vale AB’s exercise of the warrants corresponds to approximately 22 per cent of all outstanding warrants of series TO6.
The major shareholder’s decision to exercise warrants to subscribe for shares is a clear signal of continued significant ownership commitment and a clear endorsement of Peptonic’s]]></description><pubDate>Mon, 08 Jun 2026 09:00:00 GMT</pubDate></item><item><title>Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care</title><link>https://news.cision.com/molnlycke/r/molnlycke-health-care-strengthens-global-manufacturing-footprint-to-power-future-growth-in-wound-car,c4357820</link><guid isPermaLink="false">cision5378935</guid><description><![CDATA[Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke[®]”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
Building on recent expansion announcements in Brunswick, USA, and Changshu, China, the coordinated investments reflect Mölnlycke’s continued focus on meeting growing demand for advanced wound care]]></description><pubDate>Mon, 08 Jun 2026 07:00:00 GMT</pubDate></item><item><title>Sectra’s year-end report 2025/2026: Long-term investments drive growth and profit</title><link>https://news.cision.com/sectra/r/sectra-s-year-end-report-2025-2026--long-term-investments-drive-growth-and-profit,c4358145</link><guid isPermaLink="false">cision5378178</guid><description><![CDATA[Press release – Linköping, June 5, 2026 – International medical imaging IT and cybersecurity company Sectra (https://sectra.com) (STO: SECT B) is continuing to take important steps in medical imaging IT and secure communications. The value of the company’s long-term investments in improved healthcare diagnostics and in society’s cyber defense is reflected in its financial performance, with historically high sales and net profit for the year. Given the year’s cash flow and Sectra’s financial position, it is proposed that the Annual General Meeting (AGM) resolve on an increased ordinary]]></description><pubDate>Fri, 05 Jun 2026 06:15:00 GMT</pubDate></item><item><title>Peptonic Medical AB announces a new date for the publication of its annual report</title><link>https://news.cision.com/peptonic-medical-ab/r/peptonic-medical-ab-announces-a-new-date-for-the-publication-of-its-annual-report,c4358137</link><guid isPermaLink="false">cision5377978</guid><description><![CDATA[Peptonic Medical AB (publ) announces that the company has decided to postpone the publication of its annual report for the 2025 financial year.
The previously announced publication date was 3 June 2026. The new publication date is 10 June 2026.

The annual report will be published on the company’s website as soon as it is finalised.

For further information, please contact:

Daniel Rudeklint, Interim CEO, Peptonic Medical AB

Email: daniel.rudeklint@peptonicmedical.se

Telephone: +46 73 158 02 73

About Peptonic Medical AB

Peptonic Medical AB (publ) is a Swedish medical]]></description><pubDate>Thu, 04 Jun 2026 16:00:00 GMT</pubDate></item><item><title>Bioretec Ltd – Manager’s transactions – van Hellenberg Hubar-Fisher</title><link>https://news.cision.com/bioretec/r/bioretec-ltd---manager-s-transactions---van-hellenberg-hubar-fisher,c4357997</link><guid isPermaLink="false">cision5377829</guid><description><![CDATA[Bioretec Ltd Company release 4 June 2026 at 14:25 p.m. EEST

 

Bioretec Ltd - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Sarah van Hellenberg Hubar-Fisher

Position: Chief Executive Officer

 Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 159307/6/8

____________________________________________

Transaction date: 2026-06-02

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000480454]]></description><pubDate>Thu, 04 Jun 2026 11:25:00 GMT</pubDate></item><item><title>Wellspect HealthCare Introduces LoFric® Origo™ Pro – Featuring 12 Smooth Eyelets</title><link>https://news.cision.com/wellspect-healthcare/r/wellspect-healthcare-introduces-lofric--origo--pro---featuring-12-smooth-eyelets,c4356664</link><guid isPermaLink="false">cision5377708</guid><description><![CDATA[Mölndal, Sweden – June 4, 2026 – Wellspect HealthCare introduces LoFric® Origo™ Pro – featuring 12 smooth eyelets designed to support complete bladder emptying and therefore reduce one of the key risk factors for urinary tract infections.
[LoFric Origo Pro simplifies learning.png]

Wellspect HealthCare today announces the launch of LoFric® Origo™ Pro. It is a single-use hydrophilic intermittent catheter for men, featuring 12 smooth Pro eyelets designed to allow for complete bladder emptying in a single uninterrupted flow. Built on the proven long-term safety, high user satisfaction, and]]></description><pubDate>Thu, 04 Jun 2026 09:30:00 GMT</pubDate></item><item><title>Clinical Laserthermia Systems publishes annual report for 2025</title><link>https://news.cision.com/cls/r/clinical-laserthermia-systems-publishes-annual-report-for-2025,c4357375</link><guid isPermaLink="false">cision5377463</guid><description><![CDATA[Lund, Sverige – Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2025.
Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2025. The report is available in Swedish on the company’s website https://clinicallaser.se/. It is also attached to this press release.

 

 

For more information, please contact:

Dan J. Mogren, CEO Clinical Laserthermia Systems AB (publ)

Phone: +46 (0)705 90 11 40

E-mail: dan.mogren@clinicallaser.com

 

 

About CLS]]></description><pubDate>Thu, 04 Jun 2026 06:30:00 GMT</pubDate></item><item><title>OssDsign Catalyst® outperforms earlier-generation bone graft as a standalone treatment in trauma study</title><link>https://news.cision.com/ossdsign-ab/r/ossdsign-catalyst--outperforms-earlier-generation-bone-graft-as-a-standalone-treatment-in-trauma-stu,c4357302</link><guid isPermaLink="false">cision5376604</guid><description><![CDATA[Uppsala, June 3, 2026. OssDsign AB (publ.) today announces the publication of a new scientific article in The Journal of Bone and Mineral Research (JBMR). The preclinical study evaluated OssDsign Catalyst as a standalone bone graft in trauma, comparing it to an earlier-generation bone graft. The results show significantly more bone formation with OssDsign Catalyst at earlier timepoints, as well as clear evidence that the graft is naturally broken down and replaced by the body over time – reinforcing the superiority of fourth-generation synthetic bone grafts like OssDsign Catalyst.
In the]]></description><pubDate>Wed, 03 Jun 2026 13:36:40 GMT</pubDate></item><item><title>OssDsign AB announces updated proposal regarding board fees ahead of the annual general meeting 2026</title><link>https://news.cision.com/ossdsign-ab/r/ossdsign-ab-announces-updated-proposal-regarding-board-fees-ahead-of-the-annual-general-meeting-2026,c4357037</link><guid isPermaLink="false">cision5376249</guid><description><![CDATA[The nomination committee of OssDsign AB (publ) (“OssDsign” or the “Company”) has updated its proposal regarding board fees ahead of the annual general meeting on 9 June 2026. The updated proposal entails that fees for work within the audit committee are added in addition to the previously proposed board fees.
The nomination committee has previously proposed that the fees payable to the board of directors for the period until the end of the next annual general meeting shall amount to a total of SEK 1,300,000, out of which SEK 400,000 shall be paid to the chairman and SEK 300,000 to each of]]></description><pubDate>Wed, 03 Jun 2026 08:21:18 GMT</pubDate></item><item><title>Peptonic Medical launches a new product segment in health and beauty – strengthening growth opportunities through a broader offering and a new brand</title><link>https://news.cision.com/peptonic-medical-ab/r/peptonic-medical-launches-a-new-product-segment-in-health-and-beauty---strengthening-growth-opportun,c4356784</link><guid isPermaLink="false">cision5376052</guid><description><![CDATA[Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is launching a new product segment within health and beauty. This initiative represents a significant broadening of the Company’s product portfolio and constitutes an important step in the long-term strategy to create new revenue streams and strengthen the market position. The launch is planned for the second half of 2026. In connection with this, the Company will also bring products together under a new common brand in accordance with the strategic development plan.
The first product will be an innovative dietary supplement developed]]></description><pubDate>Wed, 03 Jun 2026 06:30:00 GMT</pubDate></item><item><title>Corr. of press release: ChemoTech secures 6 MSEK Growth Loan from a Swedish Financial Institution</title><link>https://news.cision.com/chemotech/r/corr--of-press-release--chemotech-secures-6-msek-growth-loan-from-a-swedish-financial-institution,c4356750</link><guid isPermaLink="false">cision5375708</guid><description><![CDATA[The press release was sent 2026-06-02 at 16:16 without information about the interest rate. The interest rate is stated in bold in the press release below which is otherwise consistent with the previously issued press release.

Scandinavian ChemoTech has secured a SEK 6 million growth loan from a larger financial institution in Sweden.
The financing forms part of ChemoTech’s long-term financial strategy and will support the Company’s commercial expansion within Animal Care in North America and Europe. By strengthening sales and marketing capacity, the loan is expected to contribute to]]></description><pubDate>Tue, 02 Jun 2026 15:51:14 GMT</pubDate></item><item><title>Scandinavian ChemoTech secures SEK 6 million Growth Loan from a larger Swedish Financial Institution</title><link>https://news.cision.com/chemotech/r/scandinavian-chemotech-secures-sek-6-million-growth-loan-from-a-larger-swedish-financial-institution,c4356679</link><guid isPermaLink="false">cision5375642</guid><description><![CDATA[Scandinavian ChemoTech has secured a SEK 6 million growth loan from a larger financial institution in Sweden.
The financing forms part of ChemoTech’s long-term financial strategy and will support the Company’s commercial expansion within Animal Care in North America and Europe. By strengthening sales and marketing capacity, the loan is expected to contribute to increased revenues and accelerate the Company’s path toward profitability. It also enhances ChemoTech’s financial flexibility by enabling other funds to be reallocated toward the continued development of the TSE platform.

 

The]]></description><pubDate>Tue, 02 Jun 2026 14:16:04 GMT</pubDate></item><item><title>Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting</title><link>https://news.cision.com/getinge/r/getinge-launches-vasoview-hemopro-3--advancing-endoscopic-vessel-harvesting,c4356828</link><guid isPermaLink="false">cision5375550</guid><description><![CDATA[Getinge today announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. Designed for clinicians, by clinicians, the system represents the latest evolution of Getinge’s EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures.
[image]

Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a]]></description><pubDate>Tue, 02 Jun 2026 13:00:00 GMT</pubDate></item><item><title>Bioretec Ltd – Manager’s transactions – Jordy Winters</title><link>https://news.cision.com/bioretec/r/bioretec-ltd---manager-s-transactions---jordy-winters,c4356497</link><guid isPermaLink="false">cision5375323</guid><description><![CDATA[Bioretec Oy Company release 2 June 2026 at 13:25 p.m. EEST

 

Bioretec Oy - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Jordy Winters

Position: Other senior manager

 Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 158959/6/4

____________________________________________

Transaction date: 2026-05-29

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000480454

Nature of transaction:]]></description><pubDate>Tue, 02 Jun 2026 10:25:00 GMT</pubDate></item><item><title>Issue and repurchase of class C shares</title><link>https://news.cision.com/dynavox-group/r/issue-and-repurchase-of-class-c-shares,c4356195</link><guid isPermaLink="false">cision5374809</guid><description><![CDATA[The Board of Directors of Dynavox Group AB today resolved to carry out three share issues of in total 754,000 new class C shares and to immediately thereafter repurchase the 754,000 newly issued class C shares. Today’s resolutions by the Board of Directors were passed by virtue of the authorisations granted by the Annual General Meeting on 8 May 2026.

DNB Bank ASA, Sweden Branch subscribed for all issued class C shares at a subscription price corresponding to the quota value of the share. All issued class C shares were thereafter repurchased by Dynavox Group AB for the same price per]]></description><pubDate>Mon, 01 Jun 2026 19:57:27 GMT</pubDate></item><item><title>The Board of Directors of Bioretec Ltd resolved on a new stock option plan</title><link>https://news.cision.com/bioretec/r/the-board-of-directors-of-bioretec-ltd-resolved-on-a-new-stock-option-plan,c4356170</link><guid isPermaLink="false">cision5374762</guid><description><![CDATA[Bioretec Ltd Company Announcement     1 June 2026 at 19:05 p.m. EEST

 

THE BOARD OF DIRECTORS OF BIORETEC LTD RESOLVED ON A NEW STOCK OPTION PLAN

The Board of Directors of Bioretec Ltd has resolved to establish a new stock option plan for key personnel and selected consultants of the Group. There is a weighty financial reason for the Company to issue stock options, as they are intended to form part of the incentive and commitment program for the Group's key personnel and consultants. The stock options are intended to encourage the participants to work on a long-term basis to]]></description><pubDate>Mon, 01 Jun 2026 16:05:00 GMT</pubDate></item><item><title>Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency</title><link>https://news.cision.com/bioretec/r/inside-information--bioretec-initiates-new-change-negotiations-in-production-to-enhance-operational-,c4356069</link><guid isPermaLink="false">cision5374760</guid><description><![CDATA[Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency

Bioretec Ltd — Inside information — 1 June 2026 at 19:00 EEST

 

Bioretec Ltd initiates change negotiations in accordance with the Finnish Act on Co-operation within Undertakings. The aim of the negotiations is to streamline operations and consequently to improve the company’s competitiveness and profitability. The negotiations will focus on Bioretec’s production function in Finland.

The change negotiations will commence on 8 June 2026 and are estimated to last for]]></description><pubDate>Mon, 01 Jun 2026 16:00:00 GMT</pubDate></item><item><title>The subscription price for warrants of series TO6 in Peptonic has been determined to SEK 0.0011 and the exercise period begins today</title><link>https://news.cision.com/peptonic-medical-ab/r/the-subscription-price-for-warrants-of-series-to6-in-peptonic-has-been-determined-to-sek-0-0011-and-,c4355584</link><guid isPermaLink="false">cision5374114</guid><description><![CDATA[NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.
Peptonic Medical AB ("Peptonic" or the "Company") completed during the first quarter of 2026 a rights issue of units, consisting of shares and warrants of series TO6 (the "Warrants" or “TO6”). The subscription price for the Warrants has been determined to SEK 0.]]></description><pubDate>Mon, 01 Jun 2026 06:30:00 GMT</pubDate></item><item><title>Observe Medical ASA - Annual General Meeting held</title><link>https://news.cision.com/observe-medical-asa/r/observe-medical-asa--annual-general-meeting-held,c4355142</link><guid isPermaLink="false">cision5373329</guid><description><![CDATA[Oslo, 29 May 2026

The annual general meeting of Observe Medical ASA (the "Company" or "Observe Medical", Euronext Expand ticker "OBSRV") was held today, on 29 May 2026 at 10:00 hours (CEST), at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway.

All resolutions were made in accordance with the proposals from the board of directors and the nomination committee.

A copy of the signed minutes from the Annual General Meeting of Observe Medical ASA is attached.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading]]></description><pubDate>Fri, 29 May 2026 09:37:23 GMT</pubDate></item><item><title>Peptonic Medical nears first delivery to strategic partner in the US – a key milestone in its international expansion</title><link>https://news.cision.com/peptonic-medical-ab/r/peptonic-medical-nears-first-delivery-to-strategic-partner-in-the-us---a-key-milestone-in-its-intern,c4354907</link><guid isPermaLink="false">cision5373117</guid><description><![CDATA[Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is now nearing its first delivery under the Company’s partnership agreement in the US with an established American player in the field of intimate self-care for women during and after the menopause. The agreement, which Peptonic has previously announced, covers the US, Canadian, Mexican and UK markets and involves Peptonic supplying products that are marketed and sold under the partner’s own well-known brand.
The first order, with an initial value of USD 120,000, was received in October 2025, and work on product design and delivery]]></description><pubDate>Fri, 29 May 2026 06:30:00 GMT</pubDate></item></channel></rss>